anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Disseminated Intravascular Coagulation (DIC) is a syndrome of dysregulated coagulation. Patients with sepsis are at increased risk for DIC. HMG-CoA Reductase Inhibitors (Statins) are primarily used as lipid-lowering agents; however, studies have suggested statins may possess anti-inflammatory, antithrombotic, anticoagulant, and endothelial stabilizing properties. These mechanisms may oppose those that underlie the pathogenesis of septic DIC.
METHODS: To evaluate whether statins may be protective against the development of DIC, we conducted a multi-center, retrospective case-control study where 86,638 critically ill patients admitted to the ICU with sepsis, severe sepsis or septic shock were identified during a 3-year period. Patients who developed DIC during their hospitalization were identified and stratified by whether they received a statin or not during their hospitalization. Odds ratios for development of DIC was calculated by composite of any statin, as well as low, moderate, and high intensity statins.
RESULTS: 2236 patients would develop DIC compared to 84,402 who did not. The use of any statin was associated with a reduced likelihood for developing DIC (odds ratio [OR], 0.69; 95% CI, 0.61-0.78). This was observed with use of both moderate (OR, 0.64; 95% CI, 0.53-0.77) and high (OR, 0.72; 95% CI, 0.61-0.84) but not low intensity statins (OR, 0.84; 95% CI, 0.53-1.32).
CONCLUSIONS: The use of moderate and high intensity statins was associated with a significantly reduced odds of developing DIC in critically ill patients with sepsis. This present study may be the first to suggest that statin medications may independently reduce the frequency of DIC in critically ill patients with severe sepsis or septic shock. More research is needed to investigate the potential for this class of medication to be protective against DIC.
The invention discloses separation and application of a novel strong-lytic MRSA virulent phage vB_SA_2868B2. The phage vB_SA_2868B2 was deposited under the accession number GDMCC No. 63318-B1. The phage vB_SA_2868B2 has strong killing effect on staphylococcus aureus, especially MRSA, and has a wider lysis spectrum. The phage vB_SA_2868B2 has good stability at the pH of 5.0-11 and the temperature of 25-45 ℃, does not carry any virulence or antibiotic resistance genes, has good inhibition effect on target bacteria on the surfaces of whole fat/skim milk, metal and raw meat, and can be safely applied to the prevention and control of staphylococcus aureus, especially MRSA. Meanwhile, the phage lyase is also characterized, and provides a source for developing a new lyase preparation.
The present invention provides a modified influenza viruses comprising haemagglutininand a headless haemagglutinin. The haemagglutininis provided by a source exogenous to the virus and the headless haemagglutininis encoded by the viral genome. The present disclosure also provides modified influenza viruses comprising a headless haemagglutinin. The present disclosure also provides vaccine compositions comprising the modified influenza viruses. The vaccine compositions of the present disclosure can elicit broad neutralizing antibodies and provide cross-protection across various influenza strains. Methods, compositions and cells for propagating the modified influenza viral strains related to vaccines is also provided.
Acute diverticulitis (AD) of colon is increasing in Finland. Incidence, prevalence and mortality of AD of colon are investigated during 10-year period (2009-2019) in whole country. Epidemiological data is compared to data of acute appendicitis. Nationwide data of patients with AD are asked from Finnish Institute for Health and Welfare (THL). To compare registry-based nationwide data, patient charts from electronic database of two hospitals (Mikkeli Central Hospital and Tampere University Hospital) are reviewed from same study period. Patient characteristics, medication, treatment (conservative vs surgery), recurrence of AD and long-term outcome are recorded.
Heyland et al. previously proposed a novel scoring tool, the Nutrition Risk in Critically ill (NUTRIC) score, which is the first nutritional risk assessment tool developed and validated specifically for intensive care unit (ICU) patients. Many other risk scores and assessment tools exist to quantify nutrition risk but none have been specifically designed for ICU patients. Indeed, they generally consider all critically ill patients to be at high nutritional risk. However, the recognition that not all ICU patients will respond the same to nutritional interventions was the critical concept behind the NUTRIC score. There was an interaction between mortality, nutritional intake and NUTRIC score suggesting that those with higher NUTRIC scores benefited the most from increasing nutritional intake. However, the inferences about the validity of the NUTRIC score are limited in Chinese patients because of no data.

The current outbreak of novel coronavirus was first reported from Wuhan, China on Dec ember 31 , 2019 . This virus was named as 2019 nCoV by World Health Organization ( on Jan uary 12 , 2020). Following the advice of the Emergency Committee, the WHO declared the outbreak of 2019 nCoV a Public Health Emergency of International Concern . Patients show fever and / or respiratory symptoms, with the imaging characteristics of pneumonia, and other symptoms include hemoptysis muscle pain, headache, confusion, chest pain, and diarrhea. About 16% patients need ICU admission.

The objective of this study is to validation of the "NUTRIC" nutritional risk assessment tool in Chinese ICU patients diagnosed as COVID-19. This is a single-center, prospective cohort study of ICU patients with COVID-19. Data for all variables of the NUTRIC score will be collected. These include age, APACHE II score, SOFA score, number of co-morbidities, days from hospital admission to ICU admission. A logistic model including the NUTRIC score, the nutritional adequacy and their interaction will be estimated to assess if the NUTRIC score modified the association between nutritional adequacy and 28-day mortality.
The present invention relates to isolated single-domain antibodies (sdAb) directed against Antithrombin (AT) to prolong the half-life of the proteins. Inventors have generated isolated single domain antibodies (sdAbs) directed against antithrombin. They observed that in amidolytic assays, sdAbs are incapable of blocking the inhibitory antithrombin activity towards thrombin and factor Xa in the presence of heparin. The different combinations of sdAb were able to block the inhibitory antithrombin activity towards thrombin and factor Xa in mice. Thus, the inventors propose to use different combinations of sdAb to block the inhibitory function of antithrombin in order to promote thrombin generation and thus treat haemophilia and other conditions that are associated with bleeding. Accordingly, the invention relates also to a method of preventing or treating bleeding disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the single domain antibodies or the drug conjugate of the invention.
Phaeohyphomycosis is caused by dematiaceous (pigmented) fungi. Most phaeohyphomycosis is non-invasive infections, however, they can lead to invasive infections, including fungemia and disseminated disease, particularly in severely immunocompromised patients. Invasive phaeohyphomycosis has recently emerged, however, the treatment strategy was not determined because of the intrinsic resistance to antifungals and the lack of clinical experience. Here, we describe a novel case of echinocandin-breakthrough Coniochaeta hoffmannii (Lecythophora hoffmannii) fungemia after hematopoietic stem cell transplantation, which was identified using matrix-assisted laser desorption ionization time-of-flight mass spectrometry and ribosomal RNA sequencing. The patient was a female in her 40s who had acute myeloid leukemia refractory to chemotherapy before progressing to cord blood transplantation. Before developing fungemia, the patient was administered multiple broad-spectrum antibiotics and micafungin for recurrent infections and prophylaxis. Clinical and microbiological responses to liposomal amphotericin B were poor but improved after replacement to voriconazole and engraftment. A literature review of the previously reported cases with C. hoffmannii human infections imply that disruption of the cutaneous/mucosal barrier and the use of antimicrobial agents, both antibiotics and antifungals, could incite C. hoffmannii invasive infections.
The invention relates to the field of traditional Chinese medicines, in particular to an oral traditional Chinese medicine composition for treatment of gastric cancers and a preparation method of the oral traditional Chinese medicine composition. The oral traditional Chinese medicine composition is prepared from ginsengs, pangolin scales, bezoars, cinnamon leaves, fagopyrum dibotrys, roots of cayratia trifolia, heterosmilax japonica, bungarus multicinctus, sappanwood, radix notoginseng, radix glehniae, radix astragali, rhizoma atractylodis, angelica sinensis and solanum nigrum. By means of existing traditional Chinese medical preparation technologies, the oral traditional Chinese medicine composition for treatment of the gastric cancers can be made into tablets, honeyed pills, capsules, powder, ointment, oral liquid and particles. The invention further discloses a preparation method of the oral traditional Chinese medicine composition for treatment of the gastric cancers. The oral traditional Chinese medicine composition for treatment of the gastric cancers has functions of clearing heat, removing toxicity, promoting blood circulation, removing stasis, promoting gastric mucosa regeneration and curing atrophic gastric cancers. In addition, the oral traditional Chinese medicine composition for treatment of the gastric cancers has the advantages of simplicity in preparation, convenience in taking, low cost and capability of meeting requirements of patients suffering from the gastric cancers.
The prevalence of gout has been steadily increasing and is correlated with the rising burden of obesity, chronic cardiac and renal disease; all conditions overrepresented in the Southeast U.S. - particularly in African Americans. Many patients with acute gout receive care at the emergency department (ED), particularly underserved urban populations in the Deep South. Appropriate outpatient follow-up for an acute flare after an ED visit is variable. Indeed, in a preliminary analysis of a retrospective cohort study of patients with acute gout treated at our urban medical center ED, only 46% of patients followed up with an outpatient clinician in our healthcare system within 6 months of their ED visit. Even fewer (36%) had an outpatient visit specifically addressing gout care within 6 months post-ED visit. This population of patients that seek acute gout care in the ED represent an important group that may benefit from interventions focused on improving gout quality of care, such as promoting outpatient follow-up.

While having a mechanism to identity acute gout patients in the ED is fundamental for enhancing care for patients with acute gout, recruiting people with acute gout who receive care in the ED outside regular business hours is challenging. One potential solution involves approaching patients after their ED visits remotely using patient navigators. The 36-72 hour period after their ED visit represents a critical time during which patients may be more receptive to efforts focused on improving healthy behaviors including scheduling outpatient follow-up (i.e., a "teachable moment). Patient navigators are trained, lay individuals of similar cultural background, and region, who provide personal guidance to patients and engage "hard-to-reach" groups, reduce access barriers, and encourage healthy behaviors such as engaging in outpatient chronic disease management.
The present invention discloses a medicinal preparation for treating rheumatism and rheumatoid diseases. The medicinal preparation is prepared by using radix aconiti, wild aconite, rhizoma arisaematis, pinellia tuber, frankincense, myrrh, bombyx batryticatus, periostracum cicadae, schizonepeta, pangolin, red peony root, angelica and safflower as raw materials through a scientific processing technology. The medicinal preparation is used for treating rheumatism, rheumatoid arthritis, cervical spondylosis, shoulder periarthritis, lumbar intervertebral disc protrusion, sciatica, hyperosteogeny, etc. Because the medicine is prepared from pure Chinese herbal medicine, the medicinal preparation has little toxic and side effect, and treats both the manifestation causes and the root causes of a disease. The plaster preparation is convenient to apply, has conspicuous curative effect, and has no rebounding phenomenon after healing. Besides, clinical symptoms can rapidly disappear.
This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
INTRODUCTION AND HYPOTHESIS: Pessary self-management offers benefits to women with no increased risk of complications. However, many are unwilling to self-manage, preferring clinician-led care. This study is aimed at exploring factors associated with willingness to self-manage a pessary.
METHODS: Women attending pessary clinic at a UK hospital were asked to complete a questionnaire providing responses on pessary use, comorbidities, female genital self-image, self-management experience and willingness (or not) to learn self-management. Based upon statistical advice we aimed to recruit 90 women. Data were analysed using the non-parametric Kruskal-Wallis test and Chi-squared test. Free text data were analysed thematically.
RESULTS: A total of 89 women completed the questionnaire. Thirty-three women (38%) had previously been taught pessary self-management. Of the remaining women, 12 (21%) were willing to learn, 28 (50%) were not willing and 16 (29%) were unsure. There was no correlation between female genital self-image and willingness to self-manage a pessary. Younger women were more willing to learn self-management (p =  < 0.001). Willing women were motivated by reduced follow-up visits. Self-managing women reported benefits including increased autonomy, cleanliness and giving their body "a break". Reasons discouraging women from self-managing were a lack of confidence; feeling physically unable; wanting clinician-led care; fear of problems or previous problems with their pessary.
CONCLUSIONS: Most women were either unsure about pessary self-management or unwilling to self-manage. Age was the only factor we found that had a significant relationship with willingness to self-manage a pessary. With robust self-management teaching, support and follow-up, it is likely that many of the barriers women report can be overcome.
In clinical trial and/or postmarketing experience, leukopenia/neutropenia have been reported in temporal association with antipsychotic agents, including risperidone. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and a history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or past drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy. Discontinuation of RYKINDO should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue RYKINDO in patients with absolute neutrophil count <1000/mm3 and follow their WBC until recovery.
Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign).
Inflammation can be triggered by any factor. The primary pathological manifestations can be summarized as the deterioration, exudation, and proliferation of local tissues, which can cause systemic damage in severe cases. Inflammatory lesions are primarily localized but may interact with body systems to cause provocative storms, parenchymal organ lesions, vascular and central nervous system necrosis, and other pathologic responses. Tetrandrine (TET) is a bisbenzylquinoline alkaloid extracted from the traditional Chinese herbal medicine Stephania tetrandra, which has been shown to have significant efficacy in inflammatory conditions such as rheumatoid arthritis, hepatitis, nephritis, etc., through NF-κB, MAPK, ERK, and STAT3 signaling pathways. TET can regulate the body's imbalanced metabolic pathways, reverse the inflammatory process, reduce other pathological damage caused by inflammation, and prevent the vicious cycle. More importantly, TET does not disrupt body's normal immune function while clearing the body's inflammatory state. Therefore, it is necessary to pay attention to its dosage and duration during treatment to avoid unexpected side effects caused by a long half-life. In summary, TET has a promising future in treating inflammatory diseases. The author reviews current therapeutic studies of TET in inflammatory conditions to provide some ideas for subsequent anti-inflammatory studies of TET.
The Partial Hospitalization Program (PHP) and Intensive Outpatient Program (IOP) in the Neuropsychatric Hospital at UCLA provide psychiatric services for adults and children with acute mental illness. These include voluntary programs that support individuals in their recovery with the goal to assist patients in achieving the highest level of independence. Most programs operate Monday through Friday between four to eight hours a day. Recently, the PHP and IOP programs have decided to start including mobile messaging as a part of care, helping patients to feel supported even after they have left the hospital for the day.

The purpose of this study is to evaluate the feasibility and effectiveness of their ongoing use of the Chorus Participatory Mobile Framework to support clinical care. Chorus is a framework and web application that allows users to rapidly create a broad range of automated text messaging (SMS), interactive voice (IVR), or mobile web applications using a simple and accessible visual interface without requiring any server programming. There will be two broad populations using Chorus: (1) programs (e.g. OCD Intensive Treatment Program) in which all participants will receive participatory mobile messaging and (2) programs (e.g. Adult Acute PHP) in which patients will be randomized to receive either participatory mobile messaging or no mobile messaging. Across all programs, Kandace Whiting and Armen Arevian will train PHP and IOP therapists starting with creating simple, basic, useful messaging content in Chorus to support patients in achieving program goals. Examples of messages include Cognitive Behavioral Therapy (CBT), symptom management, and stress management cues to patients in the Obsessive Compulsive Disorder Clinic, patients in the Adult Eating Disorder Clinic, and parents from The Achievement, Behavior, Cognition (ABC) Child Programs.

All participating patients receiving participatory mobile messaging will work with program staff one-on-one to tailor SMS and IVR content and design based on their own preferences. By being able to personalize the messaging, the Chorus Participatory Mobile Framework meets the capacities and preferences of the users rather than a "one-size" approach requiring adaptation of the users to the technology. Both therapists and patients will be invited to up to bi-weekly, in-person workshops specific to their program to provide feedback and input. The goal of these workshops is to further develop and refine the novel mobile interventions based on stakeholder input. The Chorus Participatory Framework will be used during the workshops to develop and test the application in real-time. Workshops will be audio and/or video recorded to document the process.
Polymeric monoliths having high stiffness and strength can be produced by heating an assembly of polymer fibres under a contact pressure to a temperature at which a proportion of the fibre is selectively melted and then compressing the assembly at a higher pressure. Preferably at least 5% of the polymer is melted so that on compression the molten materials fills the voids within the assembly. The use of polyolefin fibres especially melt spun polyethylene fibres is preferred. The products are useful e.g. as orthodontic brackets, bone prostheses and in body armour. The fibres may be in the form of aligned or twisted bundles, chopped fibre, woven mats or layers of fibres at crossing angles.
Gut dysbiosis has been associated with impaired outcomes in liver and kidney transplant recipients, but the gut microbiome of lung transplant recipients has not been extensively explored. We assessed the gut microbiome in 64 fecal samples from end-stage lung disease patients before transplantation and 219 samples from lung transplant recipients after transplantation using metagenomic sequencing. To identify dysbiotic microbial signatures, we analyzed 243 fecal samples from age-, sex-, and BMI-matched healthy controls. By unsupervised clustering, we identified five groups of lung transplant recipients using different combinations of immunosuppressants and antibiotics and analyzed them in relation to the gut microbiome. Finally, we investigated the gut microbiome of lung transplant recipients in different chronic lung allograft dysfunction (CLAD) stages and longitudinal gut microbiome changes after transplantation. We found 108 species (58.1%) in end-stage lung disease patients and 139 species (74.7%) in lung transplant recipients that were differentially abundant compared with healthy controls, with several species exhibiting sharp longitudinal increases from before to after transplantation. Different combinations of immunosuppressants and antibiotics were associated with specific gut microbial signatures. We found that the gut microbiome of lung transplant recipients in CLAD stage 0 was more similar to healthy controls compared to those in CLAD stage 1. Finally, the gut microbial diversity of lung transplant recipients remained lower than the average gut microbial diversity of healthy controls up to more than 20 years post-transplantation. Gut dysbiosis, already present before lung transplantation was exacerbated following lung transplantation.IMPORTANCEThis study provides extensive insights into the gut microbiome of end-stage lung disease patients and lung transplant recipients, which warrants further investigation before the gut microbiome can be used for microbiome-targeted interventions that could improve the outcome of lung transplantation.